Rumors of PRA heading back to Wall Street were greatly exaggerated, it turns out, as private equity giant KKR has agreed to snatch up the global CRO for $1.3 billion.
India's GVK Biosciences has added another big name to its list of clients, licensing its proprietary databases to help the FDA identify alternative indications for drugs already on the market, seeing if they can treat neglected and orphan diseases.
As more and more sponsors look for cost-effective solutions and shun preferred-provider relationships, CRO giant Parexel has launched a new functional service offering for pick-and-choose drug developers.
While academic partnerships are nothing new in the CRO world, lately companies have been pairing up with schools to create degree programs designed to identify the next crop of clinical research talent, and now Icon and ClinTec have added their names to that list.
German contract researcher CRS has inked a deal with Bayer, signing up to conduct Phase I and II trials for cardiovascular and women's health treatments.
Fresh off a private equity cash infusion, Australian CRO Novotech is expanding into Hong Kong and the Philippines, part of its ongoing effort to tap clinical trial demand in Asia.
In its 9 years in operation, PatientsLikeMe has recruited more than 200,000 members, culling data on symptoms, treatments and responses from disease sufferers around the world. Now, in its first deal with a CRO, the company has paired up with inVentiv Health to help recruit for clinical trials.
Contract manufacturer Ash Stevens has signed on to manufacture the API for Ariad's recently approved leukemia drug.
Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.
Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
With an eye on the rising demand for innovative dosing solutions, Catalent is expanding its capabilities in controlled-release manufacturing, planning to spend $35 million to expand a Kentucky facility.
Almac is expanding its contract manufacturing presence in Ireland, spending about $21.5 million to bolster a production facility and add 229 jobs.
MPI Research is joining forces with InviCRO and 3D Imaging to open a state-of-the-art imaging center for drug discovery and development, pooling resources to create a one-stop shop.
U.K. CRO Chiltern hauled in $137.5 million in fiscal 2012, good for 16.8% growth over the previous year.
AstraZeneca is piecing together a team of contractors for its almost virtual neuroscience unit, and the company has signed up with ePharmaSolutions to create a network that will unite its many outsourcers.
Celerion is looking to amp up its share of the biologics and vaccine development markets, launching a new containment room at its Belfast facility that will allow it to compete for study contracts.
As PRA mulls an IPO, three private equity heavyweights are reportedly looking to bid on the CRO, and current owner Genstar Capital could well be pushing talk of going public just to tick up the asking price.
Banner acquisition gives Patheon four new plants and 1,200 additional employees, which the company hopes will help it cross $1 billion in annual revenue this year.
Boehringer Ingelheim sees a wealth of opportunity in China's burgeoning pharma scene, and the German drug giant is plotting to open a contract manufacturing facility in Shanghai to cash in on biologics demand.
French contract manufacturer Unither has acquired a Rochester, NY, facility from Belgium's UCB, planning to keep all 250 employees and 50 contract workers.